Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2951–3000 of 75328
On April 26, 2026, Aspira Women's Health, Inc. (the "Company") appointed John Strahley as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026.
Christopher Meyer’s service as the Company’s interim principal financial officer and principal accounting officer will conclude on May 31, 2026, in connection with the expiration of his independent contractor agreement with the Company, dated November 28, 2025, and the appointment of Mr. Graff as the Company’s principal financial officer and principal accounting officer on such date.
On April 29, 2026, Red Robin Gourmet Burgers, Inc. (the “Company”) appointed Mark Graff to the position of Chief Financial Officer, effective May 4, 2026.
the Board of Directors of the Company appointed Mr. Gaudette as President of the Company, effective January 6, 2026, and as Chief Executive Officer, effective April 30, 2026.
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director...
On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board...
On the Effective Date, Mr. Sauer will cease serving as the Company’s Interim Chief Financial Officer and will continue serving as Vice President, Chief Accounting Officer.
On April 30, 2026, Entegris, Inc., a Delaware corporation (the “Company”), announced the appointment of Sukhi Nagesh as the Company’s Senior Vice President and Chief Financial Officer, effective as of May 18, 2026.
Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.
On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.
On April 26, 2026, the Board of Directors (the "Board") of Regional Health Properties, Inc. (the "Company") appointed Marlie Davis, CPA, MBA, as the Company’s Chief Financial Officer, effective May 1, 2026.
On April 27, 2026, Christopher Winkle notified the Company of his resignation from the Board, effective May 31, 2026.
appointed Andrew Fentress as the Company’s Managing Director – Capital Markets
On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc.
Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.
On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.
On April 27, 2026, Brian Herb, Executive Vice President, Chief Financial and Administrative Officer of CCC Intelligent Solutions Holdings Inc. (the “Company”), notified the Company that he will resign from his role with the Company effective May 25, 2026, to accept another opportunity.
Mr. Sabol will replace Mr. Mark Weaver, who was serving as Interim Chief Financial Officer until the Company hire a permanent Chief Financial Officer.
On April 24, 2026, the Board of Directors of Amtech Systems, Inc. (the “Company”) approved the appointment of Mr. Thomas Sabol as the Company’s Chief Financial Officer, effective May 14, 2026
On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.
On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
and Diego Scotti will cease to serve as the EVP, General Manager, Consumer Group of the Company
On April 29, 2026, PayPal Holdings, Inc. (the " Company ") announced that, effective as of June 2, 2026, Michelle Gill will cease to serve as the EVP, General Manager, Small Business and Financial Services of the Company
On April 29, 2026, the Board of Directors (the “Board”) of Fermi Inc. (the “Company) appointed Robert L. Masson as Interim Chief Financial Officer (“Interim CFO”) and the principal financial officer of the Company effective April 29, 2026, until a permanent successor is named.
the Board announced that Christopher Volker, the Company’s Chief Operating Officer, will succeed Mr. McClurg as the Company’s Chief Financial Officer effective as of July 1, 2026.
On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the "Company") of his intention to retire as the Company’s Chief Financial Officer.
As a result of his termination for Cause, Mr. Neugebauer was automatically removed from the Company’s board of directors.
On April 30, 2026, the Company terminated Mr. Toby Neugebauer’s employment for Cause pursuant to his Employment Agreement as a result of conduct in violation of the terms of such agreement and of Company policies.
On April 27, 2026, William F. Greene notified Moving iMage Technologies, Inc. (the “Company”) of his retirement and resignation from his position as Chief Financial Officer of the Company effective April 27, 2026.
The Board of Directors of the Company named Bart Bedard (“Bedard ”), age 70, as Chie f Financial Officer of the Company, effective April 27, 2026.
the Company’s Board of Directors (the “ Board ”) unanimously appointed Nancy Saitta and Leilani Bradford to serve as directors of the Company, to fill two newly created seats on the Board.
the Company’s Board of Directors (the “ Board ”) unanimously appointed Nancy Saitta and Leilani Bradford to serve as directors of the Company, to fill two newly created seats on the Board.
Effective as of April 27, 2026, the following individuals were appointed to the board of directors (the “Board”) of the Company: Arin Vahanian, Hao Shen and Joel A. Gallo.
Effective as of April 27, 2026, the following individuals were appointed to the board of directors (the “Board”) of the Company: Arin Vahanian, Hao Shen and Joel A. Gallo.
Effective as of April 27, 2026, the following individuals were appointed to the board of directors (the “Board”) of the Company: Arin Vahanian, Hao Shen and Joel A. Gallo.
On April 27, 2026 the board of directors (the “ Board ”) of Bonk, Inc. (the “ Company ”) appointed Mitchell Rudy to serve as President of the Company, effective immediately.
Mr. Blackman succeeds Mr. Drapczuk as the Company’s principal financial officer and principal accounting officer.
the Board of Directors of the Company (the “ Board ”) appointed Ian Blackman, age 58, as Chief Financial Officer of NexGel, Inc. (the “ Company ”), effective April 27, 2026.
On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.
appointed Jim S. Holotik to serve as a director on the board of directors of the General Partner
On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
In connection with Mr. Lagi’s appointment as Chief Financial Officer, Nathan Kroeker will cease serving as the interim Chief Financial Officer of the Company and will continue to serve as the Company’s Chief Commercial Officer.
On April 30, 2026, Eos Energy Enterprises, Inc. (“Eos” and, together with its subsidiaries, the “Company”) announced that, effective June 8, 2026, Alessandro Lagi will be the new Chief Financial Officer of the Company.
the board of directors (our Board) of Health Catalyst, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Steven Nelson to the Board, effective May 1, 2026.
On April 28, 2026, the Bank appointed Alfred T. (“Al”) Rogers, Jr. to serve as its President, Chief Executive Officer, and Principal Executive Officer, and as a member of its board of directors.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.